YIH
IMDX

Y-Intercept (HK)’s Insight Molecular Diagnostics IMDX Stock Holding History

Y-Intercept (HK)’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-573
Closed -$8.37K – 1246
2022
Q3 		$8.37K Sell
573
-777
-58% -$13.5K ﹤0.01% 923
2022
Q2 		$24K Buy
+1,350
New +$30.7K ﹤0.01% 784

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Y-Intercept (HK)'s IMDX Position: Q4 2022 in Review

Y-Intercept (HK) sold out of Insight Molecular Diagnostics (IMDX) in Q4 2022, closing a stake of 573 shares — an estimated $8.37K sold.

Y-Intercept (HK) first reported a position in IMDX in Q2 2022 and held it in 2 quarters. The position peaked at $24K in Q2 2022. 58 funds tracked by Wall St. Rank hold IMDX as of Q4 2022.

  • Y-Intercept (HK) reported no remaining Insight Molecular Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Y-Intercept (HK) sold 573 Insight Molecular Diagnostics shares in Q4 2022, an estimated $8.37K.
  • Y-Intercept (HK) first reported a position in Insight Molecular Diagnostics in Q2 2022 and held it in 2 quarters.
  • Y-Intercept (HK)'s Insight Molecular Diagnostics position peaked at $24K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2022.

Based on Y-Intercept (HK)'s 13F filing for Q4 2022, filed 14 Feb 2023.